NEW YORK (GenomeWeb News) – Oxford Nanopore has raised £17.4 million ($28 million) in a new round of funding through existing and new investors and its marketing partner Illumina UK.

The firm is developing a nanopore-based, single-molecule sequencing platform and said that it will use the funds to accelerate development of the technology. It also said that it would use funds to support its lead project in DNA sequencing and to start early work in protein analysis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.